Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

2021年10月30日 07:00:55  [来源:]  [作者:]  [责编:admin]
字体:【

The collaboration will produce a comprehensive clinical research program in major depressive disorder and schizophrenia, building upon Boehringer Ingelheim’s circuitry-based approach to precision psychiatry and further solidifies commitment to provide better treatments for people living with serious mental health conditions.
Together, Boehringer Ingelheim and King’s College London aim to identify more patient-specific biomarkers, improving the development of therapies for cognitive impairment.

INGELHEIM, Germany & LONDON--(BUSINESS WIRE)--Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ). The study will aim to connect individual symptoms to specific brain-circuit dysfunctions, and will inform the development of novel therapies that target the underlying neurobiological processes of individual behavioral traits.

“We are delighted to collaborate with King’s IoPPN, a leading institute for research in psychiatry”, said Dr Vikas Mohan Sharma, Head of Medicine CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim. “This collaboration will advance our understanding to better assess cognition and those biomarkers linked to cognitive deterioration in people with major depressive disorder and schizophrenia. We look forward to jointly creating opportunities to accelerate future clinical trials and the development of treatments for the many people impacted by psychiatric disorders.”

The partners plan to conduct four clinical studies to assess the behaviors of people with MDD and SZ in their home environments as well as during their study center visits where the activation of brain circuits triggered by cognitive tasks will be mapped. The unique study design includes, beyond standard clinical assessments, a battery of cognitive tasks, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), polysomnography, patient functioning assessment through virtual reality tools and digital biomarkers to monitor speech and sleep habits.

“King’s College London has a long-standing focus on advancing the understanding of brain circuits responsible for cognition deficits in both psychiatric and neurological disorders,” said Professor Steven Williams, project lead and Head of Department of Neuroimaging at King’s IoPPN. “Working with Boehringer Ingelheim, a research-driven company with vast experience in central nervous system drug discovery and clinical development, will allow us to enlist their expertise in clinical study design, enable new therapeutic concepts and better clinical trials of individual patient populations.”

Neuropsychiatric disorders affect hundreds of millions of people worldwide and can impact people’s health and their ability to learn and work. Cognition is a fundamental aspect of everyday life, including problem-solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These malfunctions are common across many forms of mental disorders. Although antipsychotic medications have evolved in the 1990s since their introduction, treatment options have otherwise remained mostly unchanged. This is at least partly due to the lack of breakthrough therapies to treat severe mental health issues. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim’s innovative mental health research. The company has built a comprehensive development program in this area including two ongoing phase II trials and a recent first-of-its-kind phase III start for its novel glycine transporter-1 (GlyT1) inhibitor. The clinical study of GlyT1 is an example for the potential development of new therapeutic concepts based on better understanding of which brain circuits are relevant for cognitive impairment associated with schizophrenia.

Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/collaboration-kings-college-london

网易网友:寻找爱 Looking
评论:婚外情可以是个浪漫的故事,但离婚则是一次惨痛的事故。

淘宝网友:capital °故作
评论:唐僧骑的是神马 , 悟空腾的是浮云 , 八戒爱的是小月月 , 沙僧装的是犀利哥 。

天涯网友:不相离°  1/m*
评论:我的优点是:我很淑女;但是我的缺点是:我淑女的不明显。

天猫网友:以死换温柔◇
评论:赚钱像接露水那么辛苦,花钱却像流水那么迅速

其它网友:腐朽Eros1on
评论:快开学了,学校,你得到的我的人却得不到我的心。

搜狐网友:︶別致微笑ゞ
评论:只要爱情不要金钱的女人很多,只要爱情不要婚姻的男人更多。

猫扑网友:不在乎  End.ゝ
评论:下辈子做只考拉,每天睡觉20个小时,吃2个小时,发呆2 个小时,这就是完美人生啊。

腾讯网友:基情无处不在
评论:我愿意为你摘一颗星,只要你借给我足够高的椅子。

凤凰网友:Flowers ( 繁花 )
评论:中国高中作业一年布置3亿多字,卷子连起来可绕地球5圈,连续8年销售数量第一!

百度网友:m/m  撕心裂肺°
评论:我也曾有过一双翅膀,不过我没用它在天上翱翔,而是放在锅里炖汤

相关新闻
关于我们 | 广告服务 | 浙江热线 | 旗龙网 | 听鱼网 | 2349 | 法律声明 | 联系我们
站务及信息报错:13757197494 (非诚勿扰) | QQ:1160322105 版权所有:上海经济新闻网 未经授权禁止复制或建立镜像
相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!
中国互联网违法和不良信息举报中心  全国新闻记者证管理及核验网络系统  网络警察报警岗亭